New immunotherapy shows promise for advanced liver cancer in asian patients

NCT ID NCT05033522

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 20 times

Summary

This study tests an experimental immunotherapy called AlloStim against standard treatments (Sorafenib, Lenvatinib, or FOLFOX4) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. The main goal is to see if AlloStim helps patients live longer. The study is currently suspended.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chiangmai University

    Chiang Mai, Thailand

  • Columbia Asia Bukit Rimau

    Shah Alam, Selangor, 40460, Malaysia

  • Naresuan University Hospital

    Phitsanulok, Tha Pho, 65000, Thailand

  • Prince of Songkla University (Songklanagarind Hospital)

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Siriraj Hospital

    Bangkok Noi, Bangkok, 10700, Thailand

  • Songklanagarind Hospital

    Khon Kaen, Thailand

  • Sultan Ismail Hospital

    Johor Bahru, Johor, 81100, Malaysia

  • Sultanah Bahiyah Hospital

    Alor Star, Kedah, 05460, Malaysia

Conditions

Explore the condition pages connected to this study.